Representative Julie Johnson (D–Texas) disclosed a sale of UnitedHealth Group shares in a filing published January 15. The transaction, executed December 18 through her Chase Brokerage Account ending in 3935, involved stock valued between $1,001 and $15,000. This marks Johnson’s first reported trade in UnitedHealth Group since taking office in January 2025, and follows a batch of similar‐sized disposals across nine other blue-chip names on the same date.

In its third‐quarter report released October 28, UnitedHealth Group posted earnings per share of $2.92, surpassing the consensus estimate by $0.05. The company generated revenue of $113.16 billion, representing a 12.2% year-over-year increase, narrowly missing the analyst projection of $113.19 billion. Return on equity stood at 19.23%, while net margin was 4.04%. Analysts project full-year earnings per share of 29.54 for the fiscal year.

UnitedHealth Group declared a quarterly dividend of $2.21 per share, payable December 16 to shareholders of record as of December 8. This translates to an annualized payout of $8.84 and a dividend yield of 2.7%. The company’s payout ratio sits at 46.14%, reflecting a balance between returning capital to investors and funding continued expansion of its UnitedHealthcare and Optum platforms.

Institutional ownership in UnitedHealth Group remains high at 87.86%. During the third quarter, North Capital Inc. increased its position by 16.2%, while Sunflower Bank and Axis Wealth Partners added modest stakes. CFC Planning Co LLC initiated a new holding of 12,764 shares worth $4.4 million, ranking UNH as its fifth-largest position. On the sell-side, one firm rates the stock as Strong Buy, seventeen as Buy, nine as Hold and three as Sell. The consensus target price stands at $385.75, reflecting confidence in mid-single-digit revenue growth and stable margin expansion.